The percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with ACE-I (or ARB if ACE-I intolerant), dual anti-platelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction